Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) closed at $434.07 in the last session, down -4.82% from day before closing price of $456.04. In other words, the price has decreased by -$4.82 from its previous closing price. On the day, 1.56 million shares were traded. ALNY stock price reached its highest trading level at $457.26 during the session, while it also had its lowest trading level at $429.615.
Ratios:
We take a closer look at ALNY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 259.07. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.54. In the meantime, Its Debt-to-Equity ratio is 11.86 whereas as Long-Term Debt/Eq ratio is at 11.17.
On August 04, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $490.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 02 ’25 when Poulton Jeffrey V. sold 3,821 shares for $452.05 per share. The transaction valued at 1,727,284 led to the insider holds 54,052 shares of the business.
Greenstreet Yvonne sold 8,924 shares of ALNY for $4,034,085 on Oct 02 ’25. The Chief Executive Officer now owns 65,409 shares after completing the transaction at $452.05 per share. On Oct 02 ’25, another insider, Tanguler Tolga, who serves as the EVP, Chief Commercial Officer of the company, sold 1,405 shares for $452.05 each. As a result, the insider received 635,126 and left with 27,438 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 57346646016 and an Enterprise Value of 57395331072. As of this moment, Alnylam’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1805.62, and their Forward P/E ratio for the next fiscal year is 61.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.86 while its Price-to-Book (P/B) ratio in mrq is 244.58. Its current Enterprise Value per Revenue stands at 17.88 whereas that against EBITDA is 178.79.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.29, which has changed by 0.7190244 over the last 52 weeks, in comparison to a change of 0.18286073 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $495.55, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is -5.63%, while the 200-Day Moving Average is calculated to be 28.84%.
Shares Statistics:
According to the various share statistics, ALNY traded on average about 1.17M shares per day over the past 3-months and 1168320 shares per day over the past 10 days. A total of 131.79M shares are outstanding, with a floating share count of 126.49M. Insiders hold about 4.26% of the company’s shares, while institutions hold 97.51% stake in the company. Shares short for ALNY as of 1760486400 were 3993922 with a Short Ratio of 3.42, compared to 1757894400 on 3718643. Therefore, it implies a Short% of Shares Outstanding of 3993922 and a Short% of Float of 3.9899999999999998.
Earnings Estimates
The market rating for Alnylam Pharmaceuticals Inc (ALNY) is a result of the insights provided by 11.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $2.26, with high estimates of $3.12 and low estimates of $1.55.
Analysts are recommending an EPS of between $5.99 and $3.76 for the fiscal current year, implying an average EPS of $4.92. EPS for the following year is $10.95, with 13.0 analysts recommending between $19.87 and $6.44.
Revenue Estimates
According to 23 analysts,. The current quarter’s revenue is expected to be $1.16B. It ranges from a high estimate of $1.61B to a low estimate of $909M. As of. The current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $593.17MFor the next quarter, 23 analysts are estimating revenue of $1.24B. There is a high estimate of $1.46B for the next quarter, whereas the lowest estimate is $1.11B.
A total of 26 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $4.23B, while the lowest revenue estimate was $3.42B, resulting in an average revenue estimate of $3.69B. In the same quarter a year ago, actual revenue was $2.25BBased on 25 analysts’ estimates, the company’s revenue will be $5.32B in the next fiscal year. The high estimate is $7.42B and the low estimate is $4.34B.
